(P072) Analysis of Composite EQD2 Dose Distribution in Radiotherapy for Cervical Cancer Using Central Shielding Technique

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Three-dimensional composite dose distribution analysis plays a significant role in the correct understanding of the dose distribution of the combination of EBRT and ICBT for cervical cancer. The use of CS in radiotherapy for cervical cancer provided tumor doses higher than those referred by the Point-A dose in previous reports, with no irregularly “cold” regions around the central target.

Tomoaki Tamaki, MD, PhD, Shin-ei Noda, MD, PhD, Tatsuya Ohno, MD, PhD, Shingo Kato, MD, PhD, Takashi Nakano, MD, PhD; Saitama Medical University International Medical Center; Gunma University Graduate School of Medicine

PURPOSE: To analyze the three-dimensional equivalent dose in 2-Gy fractions (EQD2) dose distribution of external beam radiotherapy (EBRT) plus intracavitary brachytherapy (ICBT) for cervical cancer using the central shielding technique.

MATERIALS AND METHODS: In a phantom study, a whole-pelvis irradiation (WP) plan was created using the four-field box technique and pelvis irradiation with the central shielding technique (CS) using AP-PA fields with a central block having a 3-cm or 4-cm width. Three patterns of EBRT were created for WP and CS: 30 Gy/15 fractions plus 20 Gy/10 fractions (Plan 30+20); 40 Gy/20 fractions plus 10 Gy/5 fractions (Plan 40+10); and 45 Gy/25 fractions and 0 Gy (Plan 45+0). For ICBT, two plans were created using Point-A prescription: 24 Gy/4 fractions (BTPlan 24/4) for Plan 30+20 and Plan 40+10, and 28 Gy/4 fractions (BTPlan 28/4) for Plan 45+0. The physical doses were converted to EQD2, and the composite EQD2 dose distributions were analyzed.

RESULTS: In Plan 30+20 plus BTPlan 24/4 and Plan 40+10 plus BTPlan 24/4, the area covered with 60 Gy (EQD2) in the lateral direction was larger than that in Plan 45+0 plus BTPlan 28/4. There were no “cold” spots within the lateral axis, which indicates that even with the use of CS, the treatment could provide adequate dose coverage for the central tumor and the parametrial tissue. The Point-A doses of Plan 30+20 plus BTPlan 24/4, Plan 40+10 plus BTPlan 24/4, and Plan 45+0 plus BTPlan 28/4 were 78.0 Gy (CS: 3 cm) or 71.8 Gy (CS: 4 cm), 80.1 Gy (CS: 3 cm) or 77.0 Gy (CS: 4 cm), and 84.1 Gy, respectively. These values were higher than the total Point-A doses reported in previous clinical studies, which omitted the doses provided by CS. On the other hand, the coverage in the anterior-posterior direction was smaller in Plan 30+20 plus BTPlan 24/4 and Plan 40+10 plus BTPlan 24/4 as a result of CS, indicating that the high dose to the bladder and the rectum can be avoided, while the adequate tumor coverage in this direction needs to be assessed carefully.

CONCLUSIONS: Three-dimensional composite dose distribution analysis plays a significant role in the correct understanding of the dose distribution of the combination of EBRT and ICBT for cervical cancer. The use of CS in radiotherapy for cervical cancer provided tumor doses higher than those referred by the Point-A dose in previous reports, with no irregularly “cold” regions around the central target.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content